Literature DB >> 20484216

Projecting future drug expenditures--2010.

James M Hoffman1, Fred Doloresco, Lee C Vermeulen, Nilay D Shah, Linda Matusiak, Robert J Hunkler, Glen T Schumock.   

Abstract

PURPOSE: Drug expenditure trends in 2008 and 2009, projected drug expenditures for 2010, and factors likely to influence drug expenditures are discussed.
SUMMARY: Various factors are likely to influence drug expenditures in 2010, including drugs in development, the diffusion of new drugs, generic drugs, health care reform, drug safety concerns, and comparative effectiveness research. The increasing availability of important generic drugs continues to moderate growth in drug expenditures. Health care reform initiatives, including the potential for biosimilars legislation, will influence drug expenditures in all settings. From 2007 to 2008, total U.S. drug expenditures increased by 1.8%, with total spending rising from $279.6 billion to $284.7 billion. Growth in drug expenditures in clinics declined to the lowest level in a decade, a 1.0% increase from 2007 to 2008. Hospital drug expenditures increased at a moderate rate of only 2.1% from 2007 to 2008; through the first nine months of 2009, hospital drug expenditures increased by 3.0% compared with the same period in 2008.
CONCLUSION: In 2010, we project a 3-5% increase in drug expenditures in outpatient settings, a 6-8% increase in expenditures for clinic-administered drugs, and a 2-4% increase in hospital drug expenditures.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484216     DOI: 10.2146/ajhp100068

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  6 in total

1.  Accuracy of annual prescription drug expenditure forecasts in AJHP.

Authors:  Patricia L Hartke; Lee C Vermeulen; James M Hoffman; Nilay D Shah; Fred Doloresco; Katie J Suda; Edward C Li; Linda M Matusiak; Robert J Hunkler; Glen T Schumock
Journal:  Am J Health Syst Pharm       Date:  2015-10-01       Impact factor: 2.637

2.  Geographic location of antineoplastic agent clinical trials conducted in developed and developing countries.

Authors:  Feng Lu; Katie J Suda; Katherine E Marks
Journal:  Int J Clin Pharm       Date:  2012-10-10

3.  Efficacy and comparative effectiveness of sirolimus as an anticancer drug.

Authors:  Melissa Hu; Oleksandr Ekshyyan; Lilantha Herman Ferdinandez; Xiaohua Rong; Gloria Caldito; Cherie-Ann O Nathan
Journal:  Laryngoscope       Date:  2011-05       Impact factor: 3.325

4.  Improved antibiotic prescribing using indication-based clinical decision support in the emergency department.

Authors:  Foster R Goss; Kelly Bookman; Michelle Barron; Daniel Bickley; Brady Landgren; Miranda Kroehl; Kayla Williamson; Richard Zane; Jennifer Wiler
Journal:  J Am Coll Emerg Physicians Open       Date:  2020-03-13

5.  A secure distributed logistic regression protocol for the detection of rare adverse drug events.

Authors:  Khaled El Emam; Saeed Samet; Luk Arbuckle; Robyn Tamblyn; Craig Earle; Murat Kantarcioglu
Journal:  J Am Med Inform Assoc       Date:  2012-08-07       Impact factor: 4.497

6.  Antibiotic Expenditures by Medication, Class, and Healthcare Setting in the United States, 2010-2015.

Authors:  Katie J Suda; Lauri A Hicks; Rebecca M Roberts; Robert J Hunkler; Linda M Matusiak; Glen T Schumock
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 20.999

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.